Tumor Suppressor Genes in Prostate Cancer – Currently Prognostic, but Soon to Be Predictive?
Alterations in PTEN, TP53, and RB1 are powerful prognostic biomarkers that may soon become predictive guides for therapeutic decision-making in prostate cancer, especially for chemotherapy and targeted agents such as AKT inhibitors, PARP inhibitors, and LSD1 inhibitors.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience